PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

Cunningham, 2006, Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer, N Engl J Med, 80, 11, 10.1056/NEJMoa055531 2002, Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial, Lancet, 359, 1727, 10.1016/S0140-6736(02)08651-8 Gebski, 2007, Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis, Lancet Oncol, 8, 226, 10.1016/S1470-2045(07)70039-6 Kelsen, 1998, Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer, N Engl J Med, 339, 1979, 10.1056/NEJM199812313392704 Weber, 2001, Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging, J Clin Oncol, 19, 3058, 10.1200/JCO.2001.19.12.3058 Ott, 2006, Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction, J Clin Oncol, 24, 4692, 10.1200/JCO.2006.06.7801 Juweid, 2006, Positron-emission-tomography and assessment of cancer therapy, N Engl J Med, 354, 496, 10.1056/NEJMra050276 Siewert, 1998, Classification of adenocarcinoma of the oesophagogastric junction, Br J Surg, 85, 1457, 10.1046/j.1365-2168.1998.00940.x Bartels, 1998, Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer, Br J Surg, 85, 840, 10.1046/j.1365-2168.1998.00663.x Becker, 2003, Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy, Cancer, 98, 1521, 10.1002/cncr.11660 Sarbia, 2004, Pathology of upper gastrointestinal malignancies, Semin Oncol, 31, 465, 10.1053/j.seminoncol.2004.04.020 Lauren, 1965, The two histological main types of gastric carcinoma: diffuse and so-called intestinal type carcinoma: an attempt at a histo-clinical classification, Acta Pathol Microbiol Scand, 64, 31, 10.1111/apm.1965.64.1.31 Brucher, 2001, Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography, Ann Surg, 233, 300, 10.1097/00000658-200103000-00002 Flamen, 2002, Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer, Ann Oncol, 13, 361, 10.1093/annonc/mdf081 Downey, 2003, Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial, J Clin Oncol, 21, 428, 10.1200/JCO.2003.04.013 Swisher, 2004, Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer, Ann Thorac Surg, 78, 1152, 10.1016/j.athoracsur.2004.04.046 Wieder, 2004, Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment, J Clin Oncol, 22, 900, 10.1200/JCO.2004.07.122 Levine, 2006, Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer, Ann Surg, 243, 472, 10.1097/01.sla.0000208430.07050.61 Gillham, 2006, (18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response, Br J Cancer, 95, 1174, 10.1038/sj.bjc.6603412 Westerterp, 2006, Monitoring of response to pre-operative chemoradiation in combination with hyperthermia in oesophageal cancer by FDG-PET, Int J Hyperthermia, 22, 149, 10.1080/02656730500513523 Enzinger, 2003, Esophageal cancer, N Engl J Med, 349, 2241, 10.1056/NEJMra035010 Ilson, 2006, Cancer of the gastroesophageal junction: combined modality therapy, Surg Oncol Clin N Am, 15, 803, 10.1016/j.soc.2006.07.011 Das, 2004, Combined modality therapy of localized gastric and esophageal cancers, J Natl Compr Canc Netw, 4, 375, 10.6004/jnccn.2006.0032 Chong, 2005, The role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible?, Nat Clin Pract Oncol, 2, 172, 10.1038/ncponc0126 Lordick, 2004, Neoadjuvant therapy for oesophagogastric cancer, Br J Surg, 91, 540, 10.1002/bjs.4575 Ilson, 1998, Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus, J Clin Oncol, 16, 1826, 10.1200/JCO.1998.16.5.1826 Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429 Westerterp, 2005, Esophageal cancer: CT, endoscopic US, and FDG PET for assessment of response to neoadjuvant therapy—systematic review, Radiology, 236, 841, 10.1148/radiol.2363041042 Wieder, 2005, Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction, J Nucl Med, 46, 2029 Weber, 2006, Positron emission tomography as an imaging biomarker, J Clin Oncol, 24, 3282, 10.1200/JCO.2006.06.6068 Ott, 2003, Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial, J Clin Oncol, 21, 4604, 10.1200/JCO.2003.06.574 Brucher, 2001, Neoadjuvant therapy of esophageal squamous cell carcinoma: response evaluation by positron emission tomography, Ann Surg, 233, 300, 10.1097/00000658-200103000-00002 Cascini, 2006, 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer, J Nucl Med, 47, 1241 Swisher, 2002, Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy, J Thorac Cardiovasc Surg, 123, 175, 10.1067/mtc.2002.119070 Piessen, 2007, Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?, Ann Surg Oncol, 14, 2036, 10.1245/s10434-007-9405-9 Mariette, 2007, Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities, Lancet Oncol, 8, 545, 10.1016/S1470-2045(07)70172-9 Choi, 2004, 18F-FDG PET in patients with esophageal squamous cell carcinoma undergoing curative surgery: prognostic implications, J Nucl Med, 45, 1843 Walsh, 1996, A comparison of multimodal therapy and surgery for esophageal adenocarcinoma, N Engl J Med, 335, 462, 10.1056/NEJM199608153350702 Urba, 2001, Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma, J Clin Oncol, 19, 305, 10.1200/JCO.2001.19.2.305 Tepper, 2006, Superiority of trimodality therapy to surgery alone in esophageal cancer: results of CALGB 9781, J Clin Oncol, 24, 4012, 10.1200/jco.2006.24.18_suppl.4012 Fiorica, 2005, Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis, Gut, 53, 925, 10.1136/gut.2003.025080 Steyerberg, 2006, Surgical mortality in patients with esophageal cancer: development and validation of a simple risk score, J Clin Oncol, 24, 4277, 10.1200/JCO.2005.05.0658 Ilson, 2006, Phase II trial of preoperative cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy: PET scan after induction therapy may identify early treatment failure, J Clin Oncol, 24, 4023, 10.1200/jco.2006.24.18_suppl.4023